Biotechnology

India is amongst the top 12 preferred biotech destinations in the world

Last updated: March 8, 2024

India is the 3rd largest biotech destination in the Asia Pacific Region

100%

FDI through automatic route permitted for brownfield investments

No.1

producer of recombinant Hepatitis B vaccine.

World's first

developer of DNA Vaccine Against COVID-19

10x

growth over the last decade

Largest

Supplier of DPT, Measles and BCG Vaccines

Leading

destination for clinical trials, contract research, and manufacturing.

+500

USFDA approved pharma plants in India; 2nd largest outside of USA.

17%

expected CAGR between 2022 and 2025

74+

bio-incubators and 9 biotech parks, with new ones in the pipeline.

Biotechnology Ignition Grant (BIG) 2022

The objective of this scheme is to enable Biotech Startup Ecosystem in the country to become globally competitive
National Biotechnology Development Strategy 2021

To establish India as a world class bio-manufacturing hub.

Open Access Policy Of DBT And DST, Govt. of India

To support basic, transitional and applied scientific research.

Biotechnology Ignition Grant

The scheme enables technology innovators and entrepreneurs to pursue a promising technology idea, and establish and validate proof of concept (POC) for the idea.
Guidelines on Similar Biologics

The “Guidelines on Similar Biologics” prepared by Central Drugs Standard Control Organization (CDSCO) and the Department of Biotechnology (DBT) lay down the regulatory pathway for a Similar Biologic claiming to be Similar to an already authorized Reference Biologic.
National Biotechnology Parks Scheme

The Biotechnology Parks, offer facilities to Scientists, and Small and Medium sized Enterprises (SMEs) for technology incubation, technology demonstration and pilot plant studies for accelerated commercial development of innovative leads.
National Guidelines for Stem Cell Research

In recent years, stem cell research has emerged as an important area of biomedical science.
COVID-19 Research for Diagnostics, Vaccines and Therapeutics

A Research strategy has been evolved at the Department of Biotechnology (DBT) for immediate response and long-term preparedness to combat COVID-19 infection.

S&T Efforts in India on COVID-19

Vigyan Prasar (VP) has been covering the pandemic since the early days with the science communication perspective and journalistic flavour, ensuring that science and safety are the primary focus.

The DNA Technology (Use and Application) Regulation Bill - 2019

Recognizing the need for regulation of the use and application of Deoxyribonucleic Acid (DNA) technology in the country, “The DNA Technology (Use and Application) Regulation Bill - 2019”, has been formulated for establishing identity of missing persons, victims, offenders, under trials and unknown deceased persons.
Guidelines for Evaluation of Probiotics in Food

The Department of Biotechnology formulates guidelines to help conduct research in the different areas of biosciences and promote its use in the industry and utility among the people.

National Biopharma Mission

The Mission is part of an Industry-Academia collaboration that aims to make India the hub for the designing and manufacturing of biotechnological commodities.

Department of Science & Technology

+91-11-26567373, 26962819

Visit Website

The department plays a pivotal role in promotion of science & technology in the country

Biotechnology Industry Research Assistance Council

+ 91-11-24389600

Visit Website

A public sector undertaking of the Department of Biotechnology.

Council of Scientific & Industrial Research

011-23710618

Visit Website

CSIR, known for its cutting edge R&D knowledge base in diverse S&T areas, is a contemporary R&D organization.

Autonomous S&T Institutions

+91-11-26562122/25/33/44,

Visit Website

A comprehensive list of S&T research organisations around India.

Department of Biotechnology

+91-11-26511439, 26510068, 23386051

Visit Website

Department of Biotechnology (DBT) was set up in 1986, within the Ministry of Science and Technology, making India one of the first countries to have a separate department for this stream of science and technology.

Department of Biotechnology

Investment Opportunities

  • Clinical studies and drug research
  • Development of medical devices
  • R&D activity around Biosimilars
  • Secondary agriculture research
  • Biotech parks and infrastructure
Useful Links:

Key Investors

India has a well-oiled enterprise promoting machinery that is backed by strong legislative, judiciary, executive and capital establishments

Abbot Laboratories - American health care company

Sanofi Aventis - providers of diabetes drugs and vaccines

Endo Pharmaceuticals - Generics and speciality manufacturer

GE Healthcare - Medical equipment & diagnostic products

Bosch - Healthcare and medical technology manufacturer

Helix - Planning and design of healthcare facilities

BPI - IT solutions for business requirements in life sciences

Tekes - Financing research, development and innovation

ENABLING ENVIRONMENT

India has a well-oiled enterprise promoting machinery that is backed by strong legislative, judiciary, executive, and capital establishments

UPI transactions cross 100 billion mark in 2023 Read More
Govt. to highlight digital achievements in Economic Survey 2023-24 Read More
PM announces new consulates in Russia, highlights strong bilateral ties Read More
Inverted duty for textiles to be relooked amid industry pushbacks Read More
Cryptocurrency adoption in India increases by 641% in 2020 : Chainalysis report Read More
India emerges as a hub for cybersecurity startups, products Read More

News

EAM Jaishankar to meet Blinken to deepen US-India ties
September 30, 2024

External Affairs Minister S Jaishankar is scheduled to meet with …

Read More

Economic Survey 2024: Indian economy shows resilience amidst global challenges
July 22, 2024

The Indian economy has remained robust and stable, demonstrating resilience …

Read More

India Inc. confident of achieving US$ 5 trillion economy: Deloitte survey
January 24, 2024

India Inc. is optimistic about achieving a US$ 5 trillion …

Read More
View All